Search results for "Tatin"

showing 10 items of 700 documents

Upregulation of activin-B and follistatin in pulmonary fibrosis: a translational study using human biopsies and a specific inhibitor in mouse fibrosi…

2014

Background: Activins are members of the TGF-ß superfamily of growth factors. First, we identified by expression array screening that activin-B and follistatin are upregulated in human idiopathic pulmonary fibrosis (IPF). Next, we wanted to clarify their specific role in lung fibrosis formation. Methods: We used specific antibodies for activin-A and -B subunits and follistatin to measure and localize their levels in idiopathic pulmonary fibrosis and control lung biopsies. To inhibit activin signaling, we used soluble activin type IIB receptor fused to the Fc portion of human IgG1 (sActRIIB-Fc) in two different mouse models of pulmonary fibrosis. Results: Activin-B and follistatin mRNA levels…

MalePathologyFollistatinPulmonary FibrosisPROTEINCell CountQuadriceps MuscleACTIVATIONIdiopathic pulmonary fibrosisMiceBMP-7FibrosisPulmonary fibrosisfollistatinInhibin-beta SubunitsGREMLINImmunity Cellularmedicine.diagnostic_testbiologyactivinsPIRFENIDONEPirfenidonerespiratory systemidiopathic pulmonary fibrosisMouse fibrosis model3. Good healthUp-RegulationActivinsmedicine.anatomical_structureACUTE EXACERBATIONmouse fibrosis modelembryonic structuresGROWTHBronchoalveolar Lavage Fluidhormones hormone substitutes and hormone antagonistsmedicine.drugResearch ArticleSignal TransductionPulmonary and Respiratory MedicineEXPRESSIONmedicine.medical_specialtyendocrine systemRecombinant Fusion ProteinseducationIdiopathic pulmonary fibrosisRespiratory MucosaAlveolar cellsINFLAMMATIONmedicineAnimalsHumansRNA MessengerLungbusiness.industrymedicine.diseaserespiratory tract diseasesMice Inbred C57BLPulmonary AlveoliDisease Models AnimalBronchoalveolar lavageProtein Biosynthesis3121 General medicine internal medicine and other clinical medicinebiology.proteinbusinessFollistatin
researchProduct

In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases

2007

Background and study aims Although various improvements in tissue imaging modalities have recently been achieved, in-vivo molecular and subsurface imaging in the field of gastroenterology remains a technical challenge. In this study we evaluated a newly developed, handheld, miniaturized confocal laser microscopy probe for real-time in-vivo molecular and subsurface imaging in rodent models of human disease. Materials and methods The minimicroscope uses a 488-nm, single line laser for fluorophore excitation. The optical slice thickness is 7 microm, the lateral resolution 0.7 microm. The range of the z-axis is 0-250 microm below the tissue surface. Imaging was performed using different fluores…

MalePathologymedicine.medical_specialtyFluorophoreLiver tumorConfocalMice Inbred StrainsOctreotidelaw.inventionIslets of LangerhansMicechemistry.chemical_compoundLiver Neoplasms ExperimentalIn vivoConfocal microscopylawMicroscopyAnimalsMedicineReceptors SomatostatinFluoresceinFluorescent DyesGastrointestinal NeoplasmsInflammationMice Inbred BALB CMicroscopy ConfocalMiniaturizationbusiness.industryGastroenterologyEquipment DesignFluoresceinsmedicine.diseaseImmunohistochemistryMice Inbred C57BLPancreatic NeoplasmsDisease Models AnimalchemistryFemaleMolecular imagingbusinessEndoscopy
researchProduct

Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly)…

2011

In 2007 the Italian COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) study group started to assess the application in a clinical setting of the Versailles criteria for management of acromegaly complications by a first questionnaire focusing on cardiovascular co-morbidities. A further questionnaire on sleep apnea syndrome (SAS) was delivered by the COM.E.T.A. study group to 107 endocrine centers in Italy. The results of our survey suggest that SAS is a well-known comorbidity even if its estimated prevalence is lower than in the literature. Polysomnography is the preferred tool for diagnosis. Control of SAS is considered relevant both for quality of life and co-morbidities. C…

MalePediatricsmedicine.medical_specialtymedicine.medical_treatmentEndocrinology Diabetes and MetabolismPolysomnographyPolysomnographyComorbiditysomatostatin analogs; acromegaly; sleep apnea syndromeSettore MED/13 - EndocrinologiaSomatostatin analogEndocrinologySleep Apnea SyndromesQuality of lifeAcromegaly; Sleep apnea syndrome; Somatostatin analogs;PhysiciansSurveys and QuestionnairesAcromegalymedicinePrevalenceHumansContinuous positive airway pressuremedicine.diagnostic_testbusiness.industrySleep apneaAwarenessFocus Groupssleep apneamedicine.diseaseComorbidityAcromegaly; Sleep apnea syndrome; Somatostatin analogsAcromegaly; Sleep ApneaSleep apnea syndromeItalySomatostatin analogsAcromegalyPhysical therapyCOM.E.TA.FemaleClinical Competencebusiness
researchProduct

Statins, Fracture Risk, and Bone Remodeling: What Is True?

2006

Besides the action on plasma lipid levels, statins show a series of ancillary effects defined as all of their vascular and nonvascular effects independent from the cholesterol reduction. It has been recently hypothesized that one of these ancillary effects could be the improvement of bone health, due to the interference with bone metabolism. This may potentially represent the rationale for statins' use in the treatment of osteoporosis, the most common disease of the bone. Both experimental observations and clinical studies on this topic generated a number of conflicting results; however, the largest randomized clinical trials, the Scandinavian Simvastatin Survival Study (4S), Long Term Inte…

MaleRiskSimvastatinmedicine.medical_specialtyOsteoporosisMyocardial IschemiaBioinformaticsBone remodelinglaw.inventionFractures Bonechemistry.chemical_compoundRandomized controlled trialRisk FactorslawHumansMedicineLongitudinal StudiesRisk factorPravastatinRandomized Controlled Trials as Topicbusiness.industryCholesterolOsteoporosiStatinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseSurgerychemistrySimvastatinOsteoporosisFemalelipids (amino acids peptides and proteins)Bone RemodelingTherapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessFracturesHeart Protection StudyPravastatinmedicine.drugThe American Journal of the Medical Sciences
researchProduct

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma

2014

Interleukin (IL)-31A binds to an heterodimer composed of IL-31 receptor A (IL-31RA) and Oncostatin M Receptor (OSMR). The IL-31/IL-31R complex is involved in the pathogenesis of various skin diseases, including cutaneous T-cell lymphoma. No information is available on the relations between the IL-31/IL-31R complex and B-cell lymphoma. Here we have addressed this issue in follicular lymphoma (FL), a prototypic germinal center(GC)-derived B-cell malignancy. IL-31 enhanced primary FL cell proliferation through IL-31R-driven signal transducer and activator of transcription factor 1/3 (STAT1/3), extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation. In contrast, GC B cells d…

MaleSTAT3 Transcription Factormedicine.medical_specialtyCancer ResearchPrimary Cell CultureFollicular lymphomaBiologyParacrine signallingCytosolCell-Derived MicroparticlesInternal medicinemedicineHumansProtein IsoformsPhosphorylationAutocrine signallingLymphoma FollicularCell ProliferationMitogen-Activated Protein Kinase 1B-LymphocytesMitogen-Activated Protein Kinase 3Gene Expression Regulation LeukemicInterleukinsMicrovesicleMedicine (all)Cell MembraneB-LymphocyteGerminal centerOncostatin M receptorInterleukinProtein IsoformReceptors InterleukinHematologyInterleukinMiddle Agedmedicine.diseaseGerminal CenterMolecular biologyCell-Derived MicroparticleEndocrinologySTAT1 Transcription FactorAnesthesiology and Pain MedicineOncologyFemaleSignal transductionNeoplasm GradingProto-Oncogene Proteins c-aktHumanSignal Transduction
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

The Tick Salivary Protein Sialostatin L Inhibits the Th9-Derived Production of the Asthma-Promoting Cytokine IL-9 and Is Effective in the Prevention …

2012

Abstract Ticks developed a multitude of different immune evasion strategies to obtain a blood meal. Sialostatin L is an immunosuppressive cysteine protease inhibitor present in the saliva of the hard tick Ixodes scapularis. In this study, we demonstrate that sialostatin L strongly inhibits the production of IL-9 by Th9 cells. Because we could show recently that Th9-derived IL-9 is essentially involved in the induction of asthma symptoms, sialostatin L was used for the treatment of experimental asthma. Application of sialostatin L in a model of experimental asthma almost completely abrogated airway hyperresponsiveness and eosinophilia. Our data suggest that sialostatin L can prevent experime…

MaleSalivaIxodidaemedicine.medical_treatmentImmunologyEnzyme-Linked Immunosorbent AssayCell SeparationBiologyReal-Time Polymerase Chain ReactionArticleNeutralizationMiceImmune systemT-Lymphocyte SubsetsmedicineAnimalsImmunology and AllergyEosinophiliaAsthmaMice KnockoutMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionInterleukin-9Flow Cytometrymedicine.diseaseCystatinsCysteine proteaseAsthmarespiratory tract diseasesDisease Models AnimalCytokineIxodes scapularisImmunologyCytokinesFemalemedicine.symptom
researchProduct

Saliva electrophoretic protein profiles in infants: changes with age and impact of teeth eruption and diet transition.

2011

International audience; Objective : The objective of this study was to describe the changes in salivary protein profiles in infants between the ages of 3 and 6 months, and to evaluate the impact of teeth eruption and introduction of solid foods on such profiles. Design : 73 infants were followed longitudinally at 3 and 6 months of age. Their whole saliva proteins were separated by SDS–PAGE electrophoresis and semi-quantified by image analysis. Amylase activity was also measured on a sub-sample of the population (n=42 infants). Bands which abundance was significantly different between the two ages according to paired comparisons were identified by mass spectrometry techniques. Results : Out …

MaleSalivaTooth eruptionPhysiologyTooth Eruption0302 clinical medicineTandem Mass Spectrometry[SDV.IDA]Life Sciences [q-bio]/Food engineeringAmylaseLongitudinal StudiesProspective Studies0303 health scienceseducation.field_of_studybiologyChemistryinfantsGeneral MedicineInfant FormulaBiochemistryAmylasesSalivary CystatinsElectrophoresis Polyacrylamide GelFemaleInfant FoodIntroduction of solid foodamylaseSpectrometry Mass Electrospray IonizationproteomePopulationslivaWeaning03 medical and health sciencesWeaningHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringCystatin AProtease InhibitorsCystatin BSalivary Proteins and PeptideseducationGeneral DentistrycystatinSerum Albumin030304 developmental biologyMilk HumanBeta-2 microglobulinSalivary CystatinsAlbuminInfant030206 dentistryCell BiologyDietSecretory ComponentOtorhinolaryngologySpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbiology.proteinproteinbeta 2-Microglobulinteeth eruptionChromatography LiquidFollow-Up StudiesArchives of oral biology
researchProduct

Fetuin-A serum levels are not correlated to kidney function in long-lived subjects

2012

Objectives: Serum Fetuin A has been identified as an inhibitor of ectopic calcification. It is reduced in subjects with chronic kidney disease (CKD) and it has been proposed as a potential link between CKD and the higher prevalence of arterial calcification observed in these patients. During ageing both the stiffening of arterial wall due to calcification and a decline in kidney function are frequent. The aim of the study is to investigate if Fetuin A serum levels are associated with ageing and with AHSG T256S polymorphism. Moreover, we aim at investigate whether serum Fetuin A is correlated to kidney function in this setting of senescence. Design and Methods: 256 health long-lived subjects…

MaleSenescenceAgingmedicine.medical_specialtyFetuin Aalpha-2-HS-GlycoproteinClinical BiochemistryGene ExpressionRenal functionKidneyKidney Function TestsPolymerase Chain ReactionPolymorphism Single NucleotideEctopic calcificationElderlyInternal medicinemedicineHumansCystatin Ckidney functionAged 80 and overbiologybusiness.industryCalcinosisGeneral MedicineSerum Fetuin AKidney diseasemedicine.diseaseFetuinArterial calcificationSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaAHSG T256S polymorphismEndocrinologyFetuin A Cystatin C Elderly Kidney disease AHSGCystatin CAHSGbiology.proteinKidney Failure ChronicFemalebusinessPolymorphism Restriction Fragment LengthCalcificationKidney disease
researchProduct

Under-prescription of statins in patients with non-alcoholic fatty liver disease

2017

Abstract Background and Aim Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders. Methods and Results Cardiovascular risk and LDL-C targets were defined according to ESC/EAS Guidelines in 605 conse…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Disease030204 cardiovascular system & hematologyEndocrinology0302 clinical medicineDrug PrescriptionNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseNutrition and DieteticPractice Patterns Physicians'Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedDiabetes and MetabolismCardiovascular DiseasesPractice Guidelines as TopicCohortUnder-prescriptionFemalelipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyGuideline AdherenceCardiology and Cardiovascular MedicineHumanAdultCardiovascular risk; Non-alcoholic fatty liver disease; Statins; Under-prescription; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyStatinmedicine.drug_classContext (language use)Health Services MisuseDrug Prescriptions03 medical and health sciencesInternal medicinemedicineHumansMedical prescriptionAgedDyslipidemiasCross-Sectional Studiebusiness.industryRisk FactorStatinsStatinnutritional and metabolic diseasesNon alcoholicBiomarkerCholesterol LDLCardiovascular riskmedicine.diseaseCross-Sectional StudiesDyslipidemiaPhysical therapyHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct